Similar to previous studies [21–23], the present meta-analysis results demonstrated that EGFR-TKI treatment of EGFR-mutant NSCLC patients improved DFS compared with non-EGFR-TKI treatment in an adjuvant setting after radical resection. Here, EGFR is linked to non-small cell lung carcinoma.